中国癌症杂志
中國癌癥雜誌
중국암증잡지
CHINA ONCOLOGY
2014年
4期
316-320
,共5页
倪晨%李婷%吴振华%胡夕春
倪晨%李婷%吳振華%鬍夕春
예신%리정%오진화%호석춘
三阴性乳腺癌%分子分型%新辅助化疗%辅助化疗%姑息化疗
三陰性乳腺癌%分子分型%新輔助化療%輔助化療%姑息化療
삼음성유선암%분자분형%신보조화료%보조화료%고식화료
Triple negative breast cancer%Molecular subtypes%Neoadjuvant chemotherapy%Adjuvant chemotherapy%Palliative chemotherapy
三阴性乳腺癌作为乳腺癌的一种特殊亚型，对内分泌治疗和现有靶向治疗无效，并且通常复发较早、进展迅速、预后较差。现就三阴性乳腺癌的分子分型及其临床价值、化疗药物和化疗方案以及化疗和潜在的新靶点药物联合方面的最新进展作一综述。
三陰性乳腺癌作為乳腺癌的一種特殊亞型，對內分泌治療和現有靶嚮治療無效，併且通常複髮較早、進展迅速、預後較差。現就三陰性乳腺癌的分子分型及其臨床價值、化療藥物和化療方案以及化療和潛在的新靶點藥物聯閤方麵的最新進展作一綜述。
삼음성유선암작위유선암적일충특수아형，대내분비치료화현유파향치료무효，병차통상복발교조、진전신속、예후교차。현취삼음성유선암적분자분형급기림상개치、화료약물화화료방안이급화료화잠재적신파점약물연합방면적최신진전작일종술。
Triple negative breast cancer (TNBC), as a special molecular subtype of breast cancer, is non-responsive to endocrine therapy or commercially available targeted therapy. It is characterized by early recurrence, rapid progression and poor prognosis. This systemic and comprehensive overview was focused on recent progress on molecular subtyping of triple negative breast cancer and its possible clinical value, chemotherapeutic agents and chemotherapy regimens, and combination of chemotherapy with potential molecular targeting agents.
